Open-label, Multicenter Trial of RSV Vaccination to Reduce Moderate-to-severe Exacerbations in COPD Frequent Exacerbators: Clinical Effectiveness and RSV-specific Immune Responses
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
Most Recent Events
- 07 Apr 2026 New trial record